Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1175621.RA6scp08hGngA0uFHBKklTZliLgllRCai1yrgQx6AHIa0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1175621.RA6scp08hGngA0uFHBKklTZliLgllRCai1yrgQx6AHIa0130_assertion type Assertion NP1175621.RA6scp08hGngA0uFHBKklTZliLgllRCai1yrgQx6AHIa0130_head.
- NP1175621.RA6scp08hGngA0uFHBKklTZliLgllRCai1yrgQx6AHIa0130_assertion description "[Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is treated with HER2-targeted agents, such as trastuzumab and lapatinib, that suppress signaling by phosphatidylinositol 3-kinase (PI3K)-Akt and MAPK pathways.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1175621.RA6scp08hGngA0uFHBKklTZliLgllRCai1yrgQx6AHIa0130_provenance.
- NP1175621.RA6scp08hGngA0uFHBKklTZliLgllRCai1yrgQx6AHIa0130_assertion evidence source_evidence_literature NP1175621.RA6scp08hGngA0uFHBKklTZliLgllRCai1yrgQx6AHIa0130_provenance.
- NP1175621.RA6scp08hGngA0uFHBKklTZliLgllRCai1yrgQx6AHIa0130_assertion SIO_000772 24754246 NP1175621.RA6scp08hGngA0uFHBKklTZliLgllRCai1yrgQx6AHIa0130_provenance.
- NP1175621.RA6scp08hGngA0uFHBKklTZliLgllRCai1yrgQx6AHIa0130_assertion wasDerivedFrom befree-2016 NP1175621.RA6scp08hGngA0uFHBKklTZliLgllRCai1yrgQx6AHIa0130_provenance.
- NP1175621.RA6scp08hGngA0uFHBKklTZliLgllRCai1yrgQx6AHIa0130_assertion wasGeneratedBy ECO_0000203 NP1175621.RA6scp08hGngA0uFHBKklTZliLgllRCai1yrgQx6AHIa0130_provenance.